Clinical psychopharmacology of pediatric mood stabilizer and antipsychotic treatment, part 1: Challenges and developments

Journal of Clinical Psychiatry

Volumn 68, Issue 8, 2007, Pages 1301-1302

  Correll, Christoph U ^a,b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; LITHIUM; MOLINDONE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; PLACEBO; QUETIAPINE; RISPERIDONE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROATE SEMISODIUM;

ADOLESCENT HEALTH; CHILD CARE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; MENTAL HEALTH; MONOTHERAPY; PRIORITY JOURNAL; PSYCHIATRIST; PSYCHOPHARMACOLOGY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCHIZOPHRENIA; SHORT SURVEY;

EID: 34548616077     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v68n0819     Document Type: Short Survey

References (26)

1. Hazell P, O'Connell D, Heathcote D, et al. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev 2002;(2):CD002317
2. Mayes TL, Tao R, Rintelmann JW, et al. Do children and adolescents have differential response rates in placebo-controlled trials of fluoxetine? CNS Spectr 2007;12:147-154
3. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 200718;297:1683-1696
4. Safer DJ. A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol 2004;24:429-436
5. Zito JM, American Society of Clinical Psychopharmacology. Pharmacoepidemiology: recent findings and challenges for child and adolescent psychopharmacology. J Clin Psychiatry 2007;68:966-967
6. Zito JM, Safer DJ, DosReis S, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med 2003;157:17-25
7. Olfson M, Blanco C, Liu L, et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry. 2006;63:679-685
8. Roberts R, Rodriguez W, Murphy D, et al. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. JAMA 2003;290:905-911
9. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006;166:1021-1026
10. Perlis RH, Miyahara S, Marangell LB, et al. Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Biol Psychiatry 2004;55:875-881
11. Häfner H, an der Heiden W. The course of schizophrenia in the light of modern follow-up studies: the ABC and WHO studies. Eur Arch Psychiatry Clin Neurosci 1999;249(suppl 4):14
12. DelBello MP, Schwiers ML, Rosenberg HL, et al. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002;41:1216-1223
13. DelBello MP, Kowatch RA, Adler CM, et al. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 2006;45:305-313
14. Wagner KD, Kowatch R, Emslie GJ, et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry 2006;163:1179-1186
15. DelBello MP, Findling RL, Kushner S, et al. A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005;44:539-547
16. Geller B, Cooper TB, Sun K, et al. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry 1998;37:171-178
17. Findling RL, McNamara NK, Youngstrom EA, et al. Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005;44:409-417
18. Calabrese JR, Shelton MD, Rapport DJ, et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005;162:2152-2161
19. Bhangoo RK, Lowe CH, Myers FS, et al. Medication use in children and adolescents treated in the community for bipolar disorder. J Child Adolesc Psychopharmacol 2003;13:515-522
20. McCracken JT, McGough J, Shah B, et al. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347:314-321
21. McDougle CJ, Scahill L, Aman MG, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 2005;162:1142-1148
22. Aman MG, Arnold LE, McDougle CJ, et al. Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol 2005;15:869-884
23. Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996;53:1090-1097
24. Shaw P, Sporn A, Gogtay N, et al. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 2006;63:721-730
25. Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry. In press
26. McClellan J, Sikich L, Findling RL, et al. The Treatment of Early-Onset Schizophrenia Spectrum Disorder (TEOSS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatr. In press